AUG 30, 2016 08:00 AM PDT

Exploring new avenues for cataract treatment using human pluripotent stem cells

Speakers
  • Director, Molecular Medicine Research Group, Western Sydney University, Australia, Senior Lecturer, School of Medicine, Western Sydney University, Australia Honorary Senior Lecturer, Save S
    Biography
      Michael uses human pluripotent cells to model macular degeneration and cataract. He received his PhD from the University of Sydney in 2005, regenerating and characterising functional ocular lenses in vitro. During postdoctoral studies in Vancouver, Canada, he identified genes related to pluripotency and played a key role in the commercial development of mTeSR1 and TeSR2 with Stem Cell Technologies. As the current President of the Australasian Society for Stem Cell Research he has developed a touring stem cell art exhibition, seen by over 1 million people, that stimulates public discussion on emerging stem cell therapies.

    Abstract:
    Cataract, or vision loss due to clouding of the eye’s lens, is a large and costly international problem. Over 80 million people currently have low vision due to cataract. Cataracts can only be treated surgically, and while this restores vision the ability to focus between near and far objects is lost. Cataract surgery is the most commonly performed ophthalmic procedure and globally costs tens of billions of dollars annually. Due to population aging the incidence of cataract is increasing, and so are the associated costs. It has been estimated that a 10-year delay in cataract formation could halve the number and costs of cataract surgery. To address this issue Dr O’Connor has developed a world-first method to produce large numbers of human lens cells from pluripotent stem cells. The ability to access unlimited numbers of human lens cells, for defining cataract risk factors and performing anti-cataract drug screening, represents a true paradigm shift in international cataract research.
     

    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    OCT 19, 2017 08:00 AM PDT
    C.E. CREDITS
    OCT 19, 2017 08:00 AM PDT
    DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    JUL 25, 2017 09:00 AM PDT
    JUL 25, 2017 09:00 AM PDT
    EVENT DETAILS:DATE: July 25, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series.  As a thought-leader in science...
    Loading Comments...